The company reported a 16% year-over-year increase in Life Sciences revenue, making up 55% of total revenue from continuing operations, with BioStorage - Bioservices revenue up 21%.

The MarketWatch News Department was not involved in the creation of this content.-- Third quarter revenue increased 15% year-over-year to $44.2 million -- Commercial Cell & Gene T ...

The agency is establishing a network of care centers to expand access to regenerative medicine beyond regions served by major ...

NEW YORK – Azalea Therapeutics launched on Tuesday, having raised $82 million in seed and Series A financing to develop in vivo genetic medicines for cancer and autoimmune conditions using its ...

People looking to lose weight and lower their blood sugar may someday be able to get a single injection that turns their ...

Vancouver, Canada, November 4th, 2025, FinanceWire Equity Insider News Commentary – The precision medicine sector reached ...

Tumors were eradicated in 30% of mice receiving cGAS LNPs injected into the tumor, in combination with immune checkpoint blockade.

In a world first, a bespoke gene-editing therapy benefited one child. Now researchers plan to launch a clinical trial of the approach ...

Azalea Therapeutics, Inc., a biotechnology company redefining precision genomic medicines in vivo, today announced its official launch and completion of $82 million in seed and Series A financing to ...

TSHA-102 granted Breakthrough Therapy designation by FDAFinalized FDA alignment on REVEAL pivotal trial protocol and SAP, including 6-month ...

A new West Coast biotech has emerged into the busy in vivo cell therapy space, this time with the backing of Nobel Prize-winning CRISPR pioneer Jennifer Doudna, Ph.D. Azalea Therapeutics has bloomed ...